Every Form 4 that Kalaris Therapeutics, Inc. (KLRS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KLRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLRS filings page.
Kalaris Therapeutics, Inc. (KLRS) reported that officer Amy O'Leary Vandekop, VP, Corporate Controller, received a grant of stock options for 10,000 shares of common stock. The options have an exercise price of $4.10 per share, expire on August 26, 2036, and vest over four years, with 25% vesting on August 1, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
Kalaris Therapeutics, Inc. reported that director Laurie Keating received a grant of stock options covering 18,000 shares of common stock, with a $3.51 exercise price and expiring on July 31, 2036. The options vest in equal monthly installments over three years from August 1, 2026 through August 1, 2029, subject to continuous service, resulting in 18,000 options directly held after this award.
Kalaris Therapeutics, Inc. reported an equity compensation grant to its Chief Financial Officer, Liisa Ann Bayko. On July 20, 2026, she received a stock option to acquire 220,000 shares of common stock at an exercise price of $4.00 per share, expiring on July 19, 2036.
According to the vesting schedule, 25% of the underlying shares vest on July 20, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service. Following this award, she holds options covering 220,000 shares.
Kalaris Therapeutics director Jovan-Embiricos Morana received a stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.7200 per share and expires on June 2, 2036. The 9,000 underlying shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholders’ meeting, subject to continued service. Following this grant, Morana holds options to purchase 9,000 shares directly.
Kalaris Therapeutics, Inc. director Ferrara Napoleone received a grant of stock options covering 9,000 shares of common stock. The options have an exercise price of $4.7200 per share and expire on June 2, 2036. The 9,000 underlying shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, subject to continued service.
Kalaris Therapeutics director David Hallal received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and was granted as compensation rather than a market purchase.
The option was granted on June 3, 2026 and is scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholder meeting, conditioned on his continued service. Following this grant, Hallal holds options for 9,000 underlying shares directly.
Kalaris Therapeutics director Srinivas Akkaraju received a grant of options to buy 9,000 shares of common stock on June 3, 2026. The options have an exercise price of $4.72 per share and expire on June 2, 2036. The underlying 9,000 shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to continued service. After this grant, the filing shows Akkaraju holding 9,000 stock options directly.
Kalaris Therapeutics, Inc. director Michael Dybbs received a grant of stock options representing 9,000 shares of Common Stock. The options have an exercise price of $4.72 per share and expire on June 2, 2036.
The shares underlying the option are scheduled to vest in full on the earlier of June 3, 2027 or the date of Kalaris Therapeutics' 2027 Annual Meeting of Stockholders, provided he continues to serve the company through that time. Following this grant, he holds 9,000 derivative securities directly.
Kalaris Therapeutics director Anthony P. Adamis received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and expires on June 2, 2036.
The shares underlying the option are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, subject to continued service. Following this grant, Adamis holds 9,000 derivative securities linked to common stock directly.
Kalaris Therapeutics director Leone D. Patterson received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and increases her directly held option position to 9,000 shares. The award was granted on June 3, 2026 and is scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholder meeting, as long as she continues in service.
Kalaris Therapeutics, Inc. reported an insider group transaction where an affiliated investment vehicle, Samsara Opportunity Fund, L.P., bought 244,300 shares of common stock at $4.83 per share in a privately negotiated deal with Samsara BioCapital, L.P.
The filing also records several non-market, pro rata in-kind distributions among related Samsara entities, reallocating a total of 86,314 shares of Kalaris common stock internally. Following the purchase, Samsara Opportunity Fund, L.P. holds 2,224,147 Kalaris shares indirectly associated with director and ten percent owner Dr. Srinivas Akkaraju.
Kalaris Therapeutics Chief Accounting Officer Brett R. Hagen reported an open-market sale of 1,915 shares of common stock at $6.72 per share, leaving no directly held common shares after the transaction. On the prior day, he received a grant of stock options for 60,800 shares of common stock at an exercise price of $6.81 per share, expiring on March 18, 2036. According to the grant terms, 25% of the underlying shares vest on March 19, 2027, with the remainder vesting in equal monthly installments thereafter, subject to continuous service. A footnote clarifies that a previous filing overstated his beneficial ownership by 10 shares, from 1,925 to 1,915, and this has now been corrected.
Kalaris Therapeutics director and officer Andrew Oxtoby received a stock option grant covering 222,000 shares of Common Stock. The option was granted as a compensation award with an exercise price of $6.8100 per share and expires on March 18, 2036.
The shares underlying the option vest over four years, with 25% vesting on March 19, 2027 and the remaining 75% vesting in equal monthly installments thereafter, subject to continuous service. Following this grant, Oxtoby holds 222,000 derivative securities directly.
Kalaris Therapeutics, Inc. reported that Chief Financial Officer Matthew Gall received a grant of stock options for 95,000 shares of common stock. The options carry an exercise price of $6.81 per share, expire on March 18, 2036, and vest over four years starting March 19, 2027.
Kalaris Therapeutics, Inc. reported that Chief Medical Officer Matthew Feinsod received a grant of stock options covering 135,000 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 18, 2036.
According to the vesting terms, 25% of the underlying shares are scheduled to vest on March 19, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service. After this grant, Feinsod holds options for 135,000 shares directly.
Kalaris Therapeutics, Inc. reported an insider-related block trade in its common stock involving affiliated investment funds. Samsara Opportunity Fund, L.P., an entity associated with director and 10% owner Srinivas Akkaraju, made an open-market style, privately negotiated purchase of 479,847 common shares at $10.42 per share from Samsara BioCapital, L.P.
Following this transaction, Samsara Opportunity Fund held 1,979,847 Kalaris Therapeutics shares, while Samsara BioCapital, L.P. held 10,968,234 shares. The filing notes that Akkaraju and related general partner entities may be deemed beneficial owners but disclaim beneficial ownership beyond their pecuniary interests, and one footnote states the transfer from Samsara BioCapital, L.P. did not change Akkaraju’s overall beneficial ownership.
Kalaris Therapeutics (KLRS) reported a Form 4 for CFO Matthew Gall, showing a grant of stock options for 235,000 shares at an exercise price of $4.99 on November 3, 2025.
The options expire on November 2, 2035 and vest over four years: 25% on November 3, 2026, then the remainder in equal monthly installments, subject to continuous service. Following the grant, 235,000 derivative securities were beneficially owned directly.